Medicenna Therapeutics Corp (MDNAF)

$1.12 +0.01 (0.90%)
Market Cap 93.42M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 209,800
Avg Vol 93,940
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 55%
Beta 1.84
Analysts Strong Sell
Price Target $4.03

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Biosectors
Biosectors Dec. 5 at 11:56 PM
$MDNAF The only silver lining I am hoping and praying is for Merck to be a little bit aggressive if data is good with combo to buy out soon since their patent cliff is expiring in 2 years or so If they need to protect their combo patent it needs more quick trials across cancer types and with their deep pocket and worldwide patient population 2026 and partly 2027 can get their patent plus data for fast track etc. it’s just a hypothetical scenario and thinking considering Merck is already in this game with MDNA for almost 1.5 years or so. Hope Merck see good data and value to make a move. If this doesn’t happen it’s a long wait till BMS see some result in Italy trial starting 2026. Let’s hope for some good data next Wednesday that market can absorb and notice.
1 · Reply
Biosectors
Biosectors Dec. 5 at 7:49 PM
$MDNAF Hmm where is he climbing down or we missing another article by him that’s not seen around here. It’s a hard call till Wednesday and 2026 is the year it may he more than 12 to 24 months from this point. Any buy out or a shocking return in few months from now will be a Santa gift and I will run to the bank so most of you here too is my guess. Good luck all and hope our patience pay in the months ahead hopefully not years
0 · Reply
Lytnup
Lytnup Dec. 5 at 7:21 PM
$MDNAF shaping up to be another decent volume day; too bad it seems to be trading that volume in a very tight range. GLTA
0 · Reply
_Osmium
_Osmium Dec. 5 at 6:29 PM
$MDNAF Today, Dave (with the Substack) clearly started climbing back in from the limb he put himself on. Citing time on the drug for his now lowered expectation of CR/PR's. Slicing his own numbers in half. As shareholders, I don't expect any fireworks next week. Just more of what we've seen. The drug is doing something but nothing yet to warrant a strong, sustained move. Hope I'm wrong about this.
1 · Reply
Spartrap
Spartrap Dec. 5 at 5:41 PM
$MDNAF after Fahar's comments on recent advances in approval of therapies delivered directly to the brain, which he sees as boosting chances of MDNA55/bizaxofusp finally finding a suitor, I did some research and found indeed the approval late last year of a gene therapy, kebilidi in aadc deficiency. https://www.icnapedia.org/education/news/10993-fda-approves-first-ever-brain-injected-gene-therapy-for-aadc-deficiency
3 · Reply
rudazur2
rudazur2 Dec. 5 at 12:31 AM
$MDNAF great volume today in canada
1 · Reply
RadOne
RadOne Dec. 5 at 12:13 AM
$MDNAF
0 · Reply
Biosectors
Biosectors Dec. 4 at 2:38 PM
$MDNAF Thank you for the update. The cORR is double with no toxicity and inpatient settings for administering MDNA11. Is that IB3163 also beta or alpha ? Beta by Medicenna is superior and miles apart in efficacy. I read conflicting news about Takeda deal where they say it’s with a chinese PD1 not globally approved with no or minimal data and some baggage as per write ups by David and Penny in their substack Is this true and relevant in this competing space .
2 · Reply
Pramdizzle
Pramdizzle Dec. 4 at 1:01 PM
$MDNAF just discovered recently. How do these stocks move when they present data (such as the event on the 10th). Do we see multiples in either direction with good/bad news?
1 · Reply
Spartrap
Spartrap Dec. 4 at 12:16 PM
$MDNAF guys, the data is maturing nicely. It's good data. The drug is safe and effective, with ORR in the 20-30 range. It's lofty. It's best in class by miles. As of early September we had at least one more response in Combination. In a couple days, we'll see the poster with all the details and 3 more months of maturity. Just to give some perspective, let me share with you the recent results of Innovent's IBI363 which was the target last month of a gigadeal by Takeda featuring $11 billion in biobucks and $1.2B upfront in cash. "IBI363 monotherapy has demonstrated breakthrough antitumor therapeutic potential, [...] As of the data cutoff date (Apr 7th, 2025) [...] the confirmed objective response rate (cORR) was 13.6%" "The combination of IBI363 and bevacizumab demonstrated encouraging efficacy signals and a manageable safety profile, with excellent data on objective response rate[...] (n=73), the cORR was 15.1%" See, that's the metrics of a "breakthrough" in advanced tumoral cancer
2 · Reply
Latest News on MDNAF
No data available.
Biosectors
Biosectors Dec. 5 at 11:56 PM
$MDNAF The only silver lining I am hoping and praying is for Merck to be a little bit aggressive if data is good with combo to buy out soon since their patent cliff is expiring in 2 years or so If they need to protect their combo patent it needs more quick trials across cancer types and with their deep pocket and worldwide patient population 2026 and partly 2027 can get their patent plus data for fast track etc. it’s just a hypothetical scenario and thinking considering Merck is already in this game with MDNA for almost 1.5 years or so. Hope Merck see good data and value to make a move. If this doesn’t happen it’s a long wait till BMS see some result in Italy trial starting 2026. Let’s hope for some good data next Wednesday that market can absorb and notice.
1 · Reply
Biosectors
Biosectors Dec. 5 at 7:49 PM
$MDNAF Hmm where is he climbing down or we missing another article by him that’s not seen around here. It’s a hard call till Wednesday and 2026 is the year it may he more than 12 to 24 months from this point. Any buy out or a shocking return in few months from now will be a Santa gift and I will run to the bank so most of you here too is my guess. Good luck all and hope our patience pay in the months ahead hopefully not years
0 · Reply
Lytnup
Lytnup Dec. 5 at 7:21 PM
$MDNAF shaping up to be another decent volume day; too bad it seems to be trading that volume in a very tight range. GLTA
0 · Reply
_Osmium
_Osmium Dec. 5 at 6:29 PM
$MDNAF Today, Dave (with the Substack) clearly started climbing back in from the limb he put himself on. Citing time on the drug for his now lowered expectation of CR/PR's. Slicing his own numbers in half. As shareholders, I don't expect any fireworks next week. Just more of what we've seen. The drug is doing something but nothing yet to warrant a strong, sustained move. Hope I'm wrong about this.
1 · Reply
Spartrap
Spartrap Dec. 5 at 5:41 PM
$MDNAF after Fahar's comments on recent advances in approval of therapies delivered directly to the brain, which he sees as boosting chances of MDNA55/bizaxofusp finally finding a suitor, I did some research and found indeed the approval late last year of a gene therapy, kebilidi in aadc deficiency. https://www.icnapedia.org/education/news/10993-fda-approves-first-ever-brain-injected-gene-therapy-for-aadc-deficiency
3 · Reply
rudazur2
rudazur2 Dec. 5 at 12:31 AM
$MDNAF great volume today in canada
1 · Reply
RadOne
RadOne Dec. 5 at 12:13 AM
$MDNAF
0 · Reply
Biosectors
Biosectors Dec. 4 at 2:38 PM
$MDNAF Thank you for the update. The cORR is double with no toxicity and inpatient settings for administering MDNA11. Is that IB3163 also beta or alpha ? Beta by Medicenna is superior and miles apart in efficacy. I read conflicting news about Takeda deal where they say it’s with a chinese PD1 not globally approved with no or minimal data and some baggage as per write ups by David and Penny in their substack Is this true and relevant in this competing space .
2 · Reply
Pramdizzle
Pramdizzle Dec. 4 at 1:01 PM
$MDNAF just discovered recently. How do these stocks move when they present data (such as the event on the 10th). Do we see multiples in either direction with good/bad news?
1 · Reply
Spartrap
Spartrap Dec. 4 at 12:16 PM
$MDNAF guys, the data is maturing nicely. It's good data. The drug is safe and effective, with ORR in the 20-30 range. It's lofty. It's best in class by miles. As of early September we had at least one more response in Combination. In a couple days, we'll see the poster with all the details and 3 more months of maturity. Just to give some perspective, let me share with you the recent results of Innovent's IBI363 which was the target last month of a gigadeal by Takeda featuring $11 billion in biobucks and $1.2B upfront in cash. "IBI363 monotherapy has demonstrated breakthrough antitumor therapeutic potential, [...] As of the data cutoff date (Apr 7th, 2025) [...] the confirmed objective response rate (cORR) was 13.6%" "The combination of IBI363 and bevacizumab demonstrated encouraging efficacy signals and a manageable safety profile, with excellent data on objective response rate[...] (n=73), the cORR was 15.1%" See, that's the metrics of a "breakthrough" in advanced tumoral cancer
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 4 at 3:17 AM
$MDNAF You are reading it the wrong way. The abstract submission date for this ESMO conference was September. So they submitted this abstract for submission back in September. End of embargo on the abstracts was today that is why it is now viewable. However ESMO states “Data and information beyond what is included in the accepted abstracts, e.g., full data sets, may only be made public at the start of the official programme session during which the study is presented.”. The “session” on Dec 10th starts at 3pm CET so we expect Medicenna to put out a presser on the up to date info ( prob till end Nov) at that time (10am EST Dec 10th)
1 · Reply
Biosectors
Biosectors Dec. 4 at 2:59 AM
$MDNAF Thank you but this poster outlined for Dec10 display and data is confusing since the body of message says as of Sep 2025 etc hope the data on Dec10 extends beyond Sep 2025 if not this poster presentation has ZERO value is my take. I wish they never released this half baked abstract mentioning Sep 2025 which has no scientific value at this point unless they update the abstract in terms of results and discussion which to me is very unlikely at this stage of conference. Last time they messed up on a good data but SP went to 2.21 and dropped due to non compliance reporting as per organizers for including data beyond cut off period. This is so convoluted and messy abstract message now.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 4 at 2:06 AM
$MDNAF Here’s the link to the abstract https://cslide.ctimeetingtech.com/coasis_21467/attendee/confcal/presentation/list?q=250P
0 · Reply
Biosectors
Biosectors Dec. 4 at 12:19 AM
$MDNAF Dec 10 data is not yet released right? hopefully Dec 10 data meet or beat Medicenna and Merck expectations for market to notice and recognize this as a potential best in class drug for unmet need either as mono or combo so all of us here can hope Merck to acquire Medicenna soon if not it’s another 12 to 24 month agonizing wait and no guarantees but I am long and wait till the end sink or swim hoping it’s worth the wait
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 4 at 12:19 AM
$MDNAF Also the Abstract notes “In addition, 1 confirmed CR (anal SCC) and 1 PR (roll-over, TMB-H neuroendocrine tumor) occurred and not included in the ORR.” If we add these two in to the combo stats, we actually get a ORR of 29%  Rock ‘n’ roll baby!
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 4 at 12:07 AM
$MDNAF Remember these are all terminal patients… 1/5 chance of a commuted death sentence, sign me up!!!!
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:57 PM
$MDNAF Here is a AI summary of how good is ORR of 20% for IO drug A 20% ORR can be enough for FDA approval for an IL-2 cancer immunotherapy, but only if: • Responses are durable • There is acceptable toxicity • The cancer setting is unmet need • Data show clear clinical benefit vs existing therapy • Ideally a CR rate is present 3%-5% I do believe we check all the boxes!!! This data cut-off is early Sept, hopefully we get up-dated data next week. With the trend in front of us, I think you can only get better.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:51 PM
$MDNAF using the same analysis that should narrow to around 21% in the combo study
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:46 PM
$MDNAF Confidence intervals are getting tighter. As more patients are enrolled we should see that become more defined. The stats should be pretty solid with current predictions based on initial conference intervals and what we have now. In mono: With the current sample size = 22 the follow-up CI (7.8%–45.4%) corresponds to 5 events (5/22 = 0.227) — i.e. an observed rate ≈ 22.7%. If that observed rate holds as we add more patients, the 95% (exact Clopper–Pearson) confidence intervals will continue to narrow to around ≈22–23%.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:25 PM
$MDNAF In combination expansioneligible indications (N=24; MDNA11 ≥ 60 μg/kg) ORR was 20.8% (95% CI 7.1-42.2%) with 5 PRs (2 MSS endometrial, 1 TMB-H breast, 1 TMB-H CRC and 1 MSI-H CRC). In addition, 1 confirmed CR (anal SCC) and 1 PR (roll-over, TMB-H neuroendocrine tumor) occurred and not included in the ORR. MDNA11 alone or with pembrolizumab induced sustained lymphocyte expansion (>14 days/dose) and increases in CD8+ T (including TCF1+ stemlike and DNAM1+ effector) and NK cells peaking at 90 μg/kg.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:17 PM
$MDNAF Conclusions MDNA11 shows a manageable safety profile and durable clinical activity as monotherapy and with pembrolizumab across multiple refractory malignancies, including ICI-progressed and immunologically ‘cold’ tumors, supporting continued evaluation in expansion cohorts.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 3 at 11:14 PM
$MDNAF Abstract out!Results As of 4 September 2025, 105 were enrolled: 58 in monotherapy and 47 in combination cohorts. No dose limiting toxicities occurred; > 90% of treatment-related adverse events were grade 1/2 and majority transient. In patients treated with MDNA11 monotherapy ≥ 60 μg/kg within expansion indications (N=22), objective response rate (ORR) was 22.7% (95% CI 7.8-45.4%): 1 confirmed complete response (CR; melanoma) and 4 partial responses (PR; 2 melanoma, 2 MSI-H PDAC). One MSI-H PDAC patient had complete regression of all lesions and remains in remission > 1.5 years post-MDNA11 without further therapy.
2 · Reply